Triheptanoin: First Approval

  • Drugs. 2020 Oct;80(15):1595-1600. doi: 10.1007/s40265-020-01399-5.
Matt Shirley  1
Affiliations
  • 1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. [email protected].
PMID: 32897506 DOI: 10.1007/s40265-020-01399-5
Abstract

Triheptanoin (Dojolvi™), a synthetic medium-chain triglyceride, is being developed by Ultragenyx Pharmaceutical as a pharmaceutical-grade anaplerotic compound for use in the treatment of inherited metabolic disorders. In June 2020, triheptanoin received its first regulatory approval, in the USA, for use as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). Triheptanoin has also been investigated for use as a treatment in a range of Other metabolic disorders or Other Diseases where energy deficiency is implicated. This article summarizes the milestones in the development of triheptanoin leading to this first regulatory approval for use in the treatment of pediatric and adult patients with LC-FAOD.

Products